Aligos Therapeutics (ALGS) executive compensation, 2026 proxy

Lawrence M. Blatt, Ph.D., M.B.A., President and Chief Executive Officer, was paid $4.1M in 2025, up 90% from $2.1M the year before.

Filed
April 29, 2026
Annual meeting
June 25, 2026
Pay year
2025
Named executives
3
CEO total pay
$4.1M+90% vs prior year
CEO Target Bonus
60%Percentage of annual base salary
Corporate Goal Achievement
95%Achieved at 95% of target
CO 401(k) Match
$12,000Maximum matching contribution
CEO 2025 Salary
$651,718Annual base salary

How M.B.A. was paid

$4.1M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary16%Option awards74%Non-equity incentive9%All other compensation0%

Named executive officers

ExecutiveTotal
Lawrence M. Blatt, Ph.D., M.B.A.President and Chief Executive Officer$4,057,234
Lesley Ann CalhounExecutive Vice President, Chief Operating Officer and Chief Financial Officer$1,579,689
Julian Symons, D.Phil.Executive Vice President, Chief Scientific Officer$1,078,522

What changed and why

  • $4.1MCEO total compensation rose to $4,057,234 in 2025 from $2,135,283 in 2024.
  • $3MOption awards for the CEO increased to $3,014,995 in 2025 compared to $1,129,049 previously.
  • 95%Annual corporate performance goals under the bonus program were achieved at 95% of target.
  • $652KThe CEO base salary was $651,718 for fiscal year 2025.
  • $12,000Executive matching 401(k) plan contributions were capped at $12,000.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.